E-resources
Peer reviewed
-
Zhang, F-R; Liu, H; Irwanto, A; Fu, X-A; Li, Y; Yu, G-Q; Yu, Y-X; Chen, M-F; Low, H-Q; Li, J-H; Bao, F-F; Foo, J-N; Bei, J-X; Jia, X-M; Liu, J; Liany, H; Wang, N; Niu, G-Y; Wang, Z-Z; Shi, B-Q; Tian, H-Q; Liu, H-X; Ma, S-S; Zhou, Y; You, J-B; Yang, Q; Wang, C; Chu, T-S; Liu, D-C; Yu, X-L; Sun, Y-H; Ning, Y; Wei, Z-H; Chen, S-L; Chen, X-C; Zhang, Z-X; Liu, Y-X; Pulit, S L; Wu, W-B; Zheng, Z-Y; Yang, R-D; Long, H; Liu, Z-S; Wang, J-Q; Li, M; Zhang, L-H; Wang, H; Wang, L-M; Xiao, P; Li, J-L; Huang, Z-M; Huang, J-X; Li, Z; Xiong, L; Yang, J; Wang, X-D; Yu, D-B; Lu, X-M; Zhou, G-Z; Yan, L-B; Shen, J-P; Zhang, G-C; Zeng, Y-X; de Bakker, P I W; Chen, S-M; Liu, J-J
The New England journal of medicine, 10/2013, Volume: 369, Issue: 17Journal Article
Dapsone is used in the treatment of infections and inflammatory diseases. The dapsone hypersensitivity syndrome, which is associated with a reported mortality of 9.9%, develops in about 0.5 to 3.6% of persons treated with the drug. Currently, no tests are available to predict the risk of the dapsone hypersensitivity syndrome. We performed a genomewide association study involving 872 participants who had received dapsone as part of multidrug therapy for leprosy (39 participants with the dapsone hypersensitivity syndrome and 833 controls), using log-additive tests of single-nucleotide polymorphisms (SNPs) and imputed HLA molecules. For a replication analysis, we genotyped 24 SNPs in an additional 31 participants with the dapsone hypersensitivity syndrome and 1089 controls and performed next-generation sequencing for HLA-B and HLA-C typing at four-digit resolution in an independent series of 37 participants with the dapsone hypersensitivity syndrome and 201 controls. Genomewide association analysis showed that SNP rs2844573, located between the HLA-B and MICA loci, was significantly associated with the dapsone hypersensitivity syndrome among patients with leprosy (odds ratio, 6.18; P=3.84×10(-13)). HLA-B*13:01 was confirmed to be a risk factor for the dapsone hypersensitivity syndrome (odds ratio, 20.53; P=6.84×10(-25)). The presence of HLA-B*13:01 had a sensitivity of 85.5% and a specificity of 85.7% as a predictor of the dapsone hypersensitivity syndrome, and its absence was associated with a reduction in risk by a factor of 7 (from 1.4% to 0.2%). HLA-B*13:01 is present in about 2 to 20% of Chinese persons, 1.5% of Japanese persons, 1 to 12% of Indians, and 2 to 4% of Southeast Asians but is largely absent in Europeans and Africans. HLA-B*13:01 was associated with the development of the dapsone hypersensitivity syndrome among patients with leprosy. (Funded by the National Natural Science Foundation of China and others.).
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.